Drug profile

The FDA adverse-event record for Porcine Insulin Zinc Suspension

40 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Porcine Insulin Zinc Suspension. Species, reactions, and outcomes follow.

#1258 of 2,679
by report volume (all drugs)
40
adverse-event reports
12.5%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Porcine Insulin Zinc Suspension ranks #1245 of 2679 by total reports (40). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1245
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Porcine Insulin Zinc Suspension has 40 reports now versus 35 in that prior snapshot: 5 more (14.3%).

Report change
+5
Death-coded reports
+1
Death-coded share
+1.1 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Porcine Insulin Zinc Suspension changes

Signature read: death-coded share at 12.5% is the most distinctive stamp on Porcine Insulin Zinc Suspension's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
40
Total Reports
5
Deaths Reported
12.5%
Death-coded share of reports

Active Ingredients

Porcine Insulin Zinc Suspension

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 32
Cat 8

Most Affected Breeds

Domestic Shorthair 6
Crossbred Canine/dog 4
Maltese 3
Chihuahua 3
Terrier - Yorkshire 3
Pinscher - Miniature 2
Himalayan 2
Bichon Frise 2
Schipperke 1
Dachshund - Miniature 1

Most Reported Reactions

Hyperglycaemia 11
Vomiting 7
Weight loss 5
Hypoglycaemia 5
Hyperkalaemia 4
Hyponatremia 4
Elevated alanine aminotransferase (ALT) 4
Diarrhoea 4
Elevated serum alkaline phosphatase (SAP) 4
Underdose 4
Lack of efficacy - NOS 4
Blindness 3

Outcome Breakdown

Outcome Unknown
21 (52.5%)
Ongoing
9 (22.5%)
Recovered/Normal
4 (10.0%)
Died
3 (7.5%)
Euthanized
2 (5.0%)
Recovered with Sequela
1 (2.5%)

Porcine Insulin Zinc Suspension Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Porcine Insulin Zinc Suspension (#1258 of 2,679 by report volume); death-coded 12.5%. PlainBreed drug row · death-coded share stamp 12.5% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →